Get the Stockscreener App
0.3248
34.77%
0.0838
Cue Biopharma Inc stock is traded at $0.3248, with a volume of 7.05M.
It is up +34.77% in the last 24 hours and down -48.10% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.241
Open:
$0.24
24h Volume:
7.05M
Relative Volume:
13.07
Market Cap:
$29.63M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.3569
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
+21.10%
1M Performance:
-48.10%
6M Performance:
-58.85%
1Y Performance:
-69.93%
1-Day Range:
$0.2381
$0.3324
1-Week Range:
$0.2302
$0.3324
52-Week Range:
$0.2302
$1.75
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.3248 | 21.99M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Cue Biopharma (CUE) price target increased by 25.00% to 5.10 - MSN
Working capital per share of Cue Biopharma, Inc. – SWB:1UC - TradingView — Track All Markets
Can Cue Biopharma Inc. stock rebound after recent weaknessTreasury Yields & Verified Swing Trading Watchlists - Улправда
Will Cue Biopharma Inc. stock see insider buyingWeekly Trade Summary & Reliable Momentum Entry Alerts - Улправда
How Cue Biopharma Inc. (1UC) stock reacts to stronger dollarMarket Activity Report & Risk Controlled Swing Trade Alerts - Улправда
Published on: 2025-12-20 23:54:48 - moha.gov.vn
Cue Biopharma Signs Underwriting Agreement With H.C. Wainwright & Co. - TradingView — Track All Markets
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Cue Biopharma prices $10 million public offering at $0.28 per share - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cue Biopharma (CUE) Launches $10 Million Public Offering with Wa - GuruFocus
Cue Biopharma prices 35.7M shares at 28c in underwritten public offering - TipRanks
Cue Biopharma (CUE) Launches $10 Million Public Offering with Warrants - GuruFocus
Cue Biopharma announces pricing of $10 million public offering - marketscreener.com
Why retail investors pile into Cue Biopharma Inc. stock2025 Valuation Update & Safe Capital Growth Plans - ulpravda.ru
Cue Biopharma Announces Pricing of $10 Million Public Offering - GlobeNewswire
Is Cue Biopharma Inc. stock attractive for growth ETFsQuarterly Profit Summary & Smart Swing Trading Alerts - Улправда
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Is Cue Biopharma Inc. (1UC) stock undervalued by metricsPortfolio Risk Report & Precise Trade Entry Recommendations - DonanımHaber
Why Cue Biopharma Inc. stock is seen as undervalued2025 Buyback Activity & Fast Gaining Stock Strategy Reports - DonanımHaber
How sustainable is Cue Biopharma Inc. stock dividend payoutQuarterly Risk Review & Safe Entry Point Alerts - DonanımHaber
Downgrade Watch: Will Cue Biopharma Inc. stock benefit from AI adoptionEarnings Recap Report & Precise Trade Entry Recommendations - Улправда
How interest rate cuts could boost Cue Biopharma Inc. stockQuarterly Performance Summary & Daily Technical Stock Forecast Reports - DonanımHaber
Cue Biopharma launches public offering of common stock and warrants By Investing.com - Investing.com Australia
Insider Trends: Why retail investors pile into Cue Biopharma Inc. stockAnalyst Downgrade & Free High Accuracy Swing Entry Alerts - Улправда
Why Cue Biopharma Inc. stock remains resilientEarnings Growth Report & Weekly Setup with ROI Potential - Bölüm Sonu Canavarı
Buybacks Report: How Cue Biopharma Inc. (1UC) stock reacts to stronger dollarJuly 2025 Reactions & Entry Point Confirmation Signals - Улправда
Will Cue Biopharma Inc. stock benefit from AI adoptionQuarterly Growth Report & Free Fast Entry Momentum Trade Alerts - Улправда
Cue Biopharma (CUE) Announces Proposed Offering with Key Managers - GuruFocus
Cue Biopharma launches proposed public offering of shares and warrants - MSN
Cue Biopharma stock tumbles on public offering announcement By Investing.com - Investing.com Canada
Cue Biopharma launches public offering of common stock and warrants - Investing.com
Cue Biopharma, Inc. Announces Underwritten Public Offering of Common Stock and Warrants - Quiver Quantitative
Cue Biopharma Announces Proposed Public Offering - GlobeNewswire
Autoimmune drug developer Cue Biopharma plans new stock and warrant sale - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Sahm
Cue Biopharma Earnings Notes - Trefis
Does Cue Biopharma Inc (CUE) offer a good opportunity for investors? - Setenews
Cue Biopharma (CUE) Price Target Increased by 25.00% to 5.10 - Nasdaq
Will Cue Biopharma Inc. stock continue upward momentum2025 Price Momentum & Fast Gain Stock Trading Tips - Newser
Is Cue Biopharma Inc. stock a safe investment in uncertain marketsDip Buying & Stepwise Trade Signal Implementation - Newser
How Cue Biopharma Inc. stock reacts to inflationary pressuresTrade Signal Summary & Real-Time Volume Triggers - Newser
Is Cue Biopharma Inc. (1UC) stock dividend growth reliableSwing Trade & Community Consensus Picks - Newser
Is Cue Biopharma Inc. (1UC) stock testing key supportStop Loss & Long-Term Safe Investment Ideas - Newser
What Wall Street predicts for Cue Biopharma Inc. stock price2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser
Will Cue Biopharma Inc. (1UC) stock benefit from infrastructure billQuarterly Earnings Report & Long-Term Capital Growth Strategies - Newser
How Cue Biopharma Inc. (1UC) stock moves in volatile trading sessionsOil Prices & High Conviction Buy Zone Alerts - Newser
Is Cue Biopharma Inc (CUE) positioned for future growth? - Setenews
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):